Nelfinavir

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Virustatic. Inhibitor of HIV protease.

IndicationThis section has been translated automatically.

Antiretroviral combination therapy for the treatment of HIV-1 infection in patients > 3 years.

Notice!

Consideration of the viral resistance pattern and pretreatment of the patient especially with other protease inhibitors!

Dosage and method of useThis section has been translated automatically.

  • Pat. > 13 y.: 3 times/day 750 mg or 2 times/day 1250 mg p.o. (to be taken with meals).
  • Pat. 3-13 yrs. 3 times/day 25-30 mg/kg bw or twice/day 50-55 mg/kg bw p.o.

Undesirable effectsThis section has been translated automatically.

Gastrointestinal symptoms such as nausea (5% of patients), diarrhea (20-30%), cutaneous NW (3-5% of patients) such as erythema, erythema exudativum multiforme, erythema nodosum. Rarely gynecomastia.

InteractionsThis section has been translated automatically.

Simultaneous administration of Nelfinavir and strong CYP 3A inhibitors such as ketoconazole, leads to an increase in the level of action of Nelfinavir.

ContraindicationThis section has been translated automatically.

Patient with severe liver and kidney dysfunction (e.g. WHO group III-IV), children < 3 years. Comedication with rifampicin or CYP3A4 substrates such as terfenadine, St. John's wort, cisapride, pimozide, antidepressants (e.g. diazepam, midazolam, flurazepam) ergotamine derivatives, astemizole, etc.

PreparationsThis section has been translated automatically.

Viracept

Authors

Last updated on: 29.10.2020